secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-09-21T23:59:59+00:00
Accession:  0001737287-22-000072
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost
--------------------------------------------------------------------------------

- Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.
- Allogene can elect ex-US license; if exercised, milestone payments for ALLO-501A increase by €46M aggregate.
- Allogene's right to recover 40% of development costs from Servier would cease upon exercise of ex-US option.
- Servier requested Allogene exercise option within limited timeframe; Cellectis challenges sublicense rights, adding legal risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/0001737287-22-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/allo-20220915.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer